After adjusting for age, disease stage, tumor differentiation, and margins in a Cox proportional hazards model, mutations in ERBB2 were significantly associated with better prognosis (a median of 27 months with ERBB2 mutant tumor, 95% CI: 4.8–49.2 months vs. a median of 20 months with ERBB2 wild‐type tumor, 95% CI: 14.7–25.3 months), and mutations in KRAS were significantly associated with worse prognosis (a median of 15 months with KRAS mutant tumor, 95% CI: 9.4–20.6 months vs. a median of 27 months with KRAS wild type tumor, 95% CI: 19.5–34.5 months), which showed in Table 2; Table S3. This evidence concerns the gene KRAS and neoplasm.